Our Platform Assimilates Data, Sees Through Complexity, and Delivers Clarity

AlphaMeld® is an AI-based, universal signal detection system built on the premise that every innovation begins with a core discovery or invention that gathers momentum. Powered by artificial intelligence and machine learning the platform accelerates innovation by identifying alpha signals of innovation for targets, drugs, and healthcare products and technologies. Primed with data sets that have been curated and connected for over a decade, the platform generates testable hypotheses based on an ideal mode of pharmacotherapy (antibody, protein replacement, siRNA, mRNA, small molecule, cell and gene therapy, and gene-editing modalities), disease severity, gene ontology, disease pathways, proteinopathies, standard of care, emerging innovation, and enabling technologies while factoring in medical, scientific, strategic, and commercial considerations. Operating in real-time, AlphaMeld® shapes and drives healthcare innovation by ensuring that the most discrete signals are detected, amplified, and taken into account.

The Groundwork

Generating the highest quality datasets is foundational to the results we acquire. We have spent over a decade curating and connecting data sets (internal and externally sourced, structured and unstructured) and continue to add new data points to ensure data reliability, validity, and relatability.


Clinical Events


Data Captured


Domain Experts




Literature / Patents






Major Diseases


Rare Diseases

Social Media





Making Biological Connections

The platform is actively learning with hundreds of industry- and disease-specific algorithms that use vast repositories of data to uncover hidden connections and build associations. Hypotheses are presented to our world-class scientists, researchers, and data scientists for rapid judgment and to further improve and accelerate every step of the innovation process.

Drug Discovery
and Development

Bringing innovative treatments to patients with unmet needs is our ultimate goal. The platform ensures that we are thorough in our quest to match the...

Right Modality To The Right Target That In Combination Is ransformational For The Right Disease

InveniAI’s AlphaMeld® platform was built to accelerate innovation by allowing our experts to rank order hypotheses for further testing. We have seen several candidates from AlphaMeld progress into clinical development.

Partner Programs and Clinical Impact

Augmenting human expertise with artificial intelligence ensures that only candidates and clinical programs with the highest likelihood of success are pursued – reducing costs and saving time and resources, and most importantly addressing an unmet need for patients across the globe.

Capturing Innovation Across Consumer-Driven Healthcare

Modern technology has brought about a new type of consumer - they are more involved, engaged, and taking control of their health by seeking products and services that create meaningful value for their day-to-day experiences. The AlphaMeld® platform allows our collaborators to identify consumer-specific innovation and convert the earliest signals of discovery into innovative products for consumers.

Access AlphaMeld®


Artificial intelligence can augment and assist human-driven processes and skills, while machine learning drives strategy but ultimately, humans remain responsible for how that information is harnessed. Our strength is based on this premise and the relentless pursuit to help our collaborators excel in achieving their goal to be at the forefront of innovation excellence. If you would like to access AlphaMeld, please contact our business development team at alphameld@inveniai.com.

Access ChatAlphaMeld

ChatAlphaMeld, a Generative AI Drug Discovery Assistant application of AlphaMeld®, is designed to transform the field of drug discovery with its advanced AI capabilities


  • ChatAlphaMeld offers a suite of AI-powered tools to enhance drug discovery and development research
  • Integrates sophisticated AI models such as GPT-4, Turbo, Mixtral, Zephyr, and fine-tuned models to address the unique challenges of drug discovery
  • Provides a range of core capabilities including enhanced natural language processing for rapid literature review and predictive analytics to inform clinical trial design, aiming to redefine research efficiency and therapeutic innovation
  • Ensures data privacy and offers a robust system of engines that empower secure, intelligent, and collaborative drug development, underpinned by a commitment to protecting user data integrity
  • Features the QC with AlphaMeld Knowledge Graph, which validates AI-generated content against a comprehensive knowledge base, keeping the platform's insights accurate and up to date with the latest pharmaceutical trends and compliance requirements

Please write to us at alphameld@inveniai.com to access the White Paper on ChatAlphaMeld.